Aurinia Pharmaceuticals Inc. (AUPH)

Over the past six months, Aurinia's stock has been impacted by several events. The company reported strong financial results for both full year 2025 and Q1 2026, with increased revenue and earnings per share. Aurinia announced a definitive agreement to acquire Kezar Life Sciences to expand its autoimmune and oncology pipeline. There was a leadership transition, with Kevin Tang appointed CEO, Ryan Cole COO, and Michael Hearne CFO. The company has been actively repurchasing shares, with 2.5 million shares repurchased in Q1 2026. As of May 8, 2026, the stock closed at $15.23, with a 52-week high of $16.88 and a low of $7.29.

The provided information does not indicate any significant demand seasonality for Aurinia Pharmaceuticals Inc.'s products or services. Demand for therapies like LUPKYNIS is generally expected to be consistent rather than seasonal due to the chronic nature of autoimmune diseases.

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases with unmet medical needs. Their primary product is LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis. The company is also advancing aritinercept (AUR200) for potential treatment of other autoimmune diseases.

Aurinia Pharmaceuticals Inc. has operations and sales in the United States and Japan, with its headquarters located in Edmonton, Canada.

Aurinia Pharmaceuticals aims to be a leading company benefiting patients suffering from autoimmune diseases. The company's reputation has been influenced by its strong financial performance and strategic acquisition of Kezar Life Sciences. A retracted LinkedIn post in November 2025 may have had an impact. Analysts generally hold a positive outlook, with a consensus "Buy" rating for the stock.

Aurinia Pharmaceuticals Inc. has a diverse ownership structure. Institutional shareholders hold approximately 54.35% of the stock, Aurinia insiders own about 13.23%, and retail investors account for 32.42%. Major institutional owners include Tang Capital Management LLC, BlackRock Inc., and NEA Management Company, LLC. Kevin Tang is the largest individual shareholder, holding 12.23 million shares, representing 9.20% of the company.